[Table_Header] 公司点评●医疗器械 2024 年 04 月 13 日 [Table_Title] [Table_StockCode] 业绩符合预期，国内外业务保持高速增长 新产业(300832) [Table_InvestRank] --2023 年年报业绩点评 推荐 (维持) 核心观点： 分析师 ⚫[T able事_S件um：m公a司ry]发 布 2023年年度报告，公司 2023年全年实现营业收入 39.30亿 [程Ta培b le_Authors] 元（+28.97%），归母净利润 16.54 亿元（+24.53%），扣非净利润 15.47 亿元 ：021-20257805 （+24.72%），经营性现金流 14.18 亿元（+47.37%）；2023Q4 实现营业收入 ：chengpei_yj@chinastock.com.cn 10.22亿元（+36.16%），归母净利润 4.67亿元（+15.77%），扣非净利润 4.46 分析师登记编码：S0130522100001 亿元（+14.98%）。 ⚫ 国内：高速机顺利推广，带动试剂销量稳步提升。2023年公司国内主营业 研究助理：孟熙 ...

2024年04月13日 公司研究●证券研究报告 新产业（ ） 公司快报 300832.SZ 医药 | 医疗器械Ⅲ 公司业绩稳定增长，海外拓展持续完善 投资评级 增持-A(维持) 股价(2024-04-12) 65.81元 投资要点 事件：公司发布2023年年度报告，2023年实现营收39.30亿元（+29%，同比增 交易数据 速，下同）；归母净利润16.54亿元（+25%）；扣非归母净利润15.47亿元（+25%）； 总市值（百万元） 51,708.15 2023Q4单季度，公司实现营收10.22亿元（+36%），实现归母净利润4.67亿元 流通市值（百万元） 45,959.94 （+16%），实现扣非归母净利润4.46亿元（+15%）。 总股本（百万股） 785.72 流通股本（百万股） 698.37 国内大型医疗终端拓展成效显著，试剂收入及单机产出快速提升。2023年国内营 12个月价格区间 81.80/52.00 收26.01 亿元（+26%），其中国内仪器类业务收入随着大型发光仪器及流水线相 关产品销量的增加带动国内仪器类产品收入同比增长 34%，高于国内业务整体增 一年股价表现 速；国内试剂业务 ...

本报告仅供 Choice 东方财富 使用，请勿传阅。 公司快报 2024 年 04 月 12 日 新 产业(300832.SZ) 证券研究报告 新产业年报点评：国内外业务各具亮 医疗器械 投资评级 买入-A 点，引领化学发光国产替代浪潮 维持评级 6 个月目标价 79.56元 事件：新产业发布 2023 年年度报告，业绩符合预期 股价 (2024-04-11) 66.43元 2023 年度，公司实现营业收入39.30 亿元，同比增长28.97%；归母 净利润 16.54亿元，同比增长24.53%；扣非归母净利润15.47 亿元， 交易数据 同比增长24.72%。2023 年度，公司综合毛利率为73.15%，同比增长 总市值(百万元) 52,195.30 2.65 个百分点，主要得益于高毛利大型仪器销售占比以及海外试剂 流通市值(百万元) 46,394.52 收入占比的双提升。分开看，试剂毛利率89.28%，同比上升 0.27 个 总股本(百万股) 785.72 百分点，仪器毛利率29.70%，同比上升 6.60 个百分点；2023 年公司 流通股本(百万股) 698.40 净利率为42.08%，同比下降 1. ...

Financial Performance - The company's operating revenue for 2023 reached ¥3,929,655,726.27, an increase of 28.97% compared to ¥3,046,955,734.50 in 2022[12]. - The net profit attributable to shareholders for 2023 was ¥1,653,653,244.98, reflecting a growth of 24.53% from ¥1,327,918,359.24 in the previous year[12]. - The net cash flow from operating activities increased by 47.37% to ¥1,418,292,417.91 in 2023, up from ¥962,391,435.81 in 2022[12]. - Basic earnings per share for 2023 were ¥2.1054, a rise of 24.53% compared to ¥1.6907 in 2022[12]. - The total assets of the company at the end of 2023 amounted to ¥8,222,488,843.69, representing a 17.22% increase from ¥7,014,554,339.23 at the end of 2022[12]. - The company's net assets attributable to shareholders increased by 17.89% to ¥7,544,400,237.20 at the end of 2023, compared to ¥6,399,494,567.56 at the end of 2022[12]. - The company reported a quarterly revenue of ¥1,042,919,865.85 in Q3 2023, with a net profit of ¥436,705,461.37 for the same quarter[13]. - The company received government subsidies amounting to ¥34,457,938.61 in 2023, up from ¥27,570,121.57 in 2022[16]. - The weighted average return on equity for 2023 was 23.72%, an increase of 1.83 percentage points from 21.89% in 2022[12]. - The company reported a total of ¥106,337,747.50 in non-recurring gains and losses for 2023, compared to ¥87,313,132.64 in 2022[16]. Market Expansion and Strategy - The company has a comprehensive strategy for market expansion, including establishing subsidiaries in various countries such as India, Pakistan, and Mexico[5]. - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its market position and expand its product range[6]. - The company has established 10 overseas subsidiaries to enhance its international market presence[25]. - The company aims to increase market share in response to the implementation of centralized procurement policies in 25 provinces, which may impact pricing[28]. - The company is focusing on expanding its product categories to meet the evolving needs of medical institutions[30]. - The company has expanded its overseas market presence, currently selling products to 152 countries and regions, with plans to implement a regional management model for better service quality[103]. - The company plans to increase the number of overseas installations to boost reagent revenue, focusing on key markets such as the EU and the US for further development[105]. Research and Development - The company has made significant investments in research and development to enhance its product pipeline and technological capabilities[6]. - The company has established four major technology platforms for in vitro diagnostic product development, including nano magnetic microspheres and fully automated diagnostic instruments[31]. - The company is currently developing 21 reagent projects, with several already submitted for regulatory review[45]. - The company has developed new products aimed at improving diagnostic capabilities and addressing clinical challenges through innovative technologies[49]. - The company is committed to continuous product and technology innovation to contribute to global health[27]. Product Offerings and Innovations - The company is focused on advancing its product offerings in in vitro diagnostics, including biochemical, immunological, and molecular diagnostics[6]. - The company has 199 reagent products available globally, with 188 having obtained EU market access, making it one of the most comprehensive suppliers in the industry[26]. - The MAGLUMI X8 instrument achieved a testing speed of 600 tests per hour, while the upcoming MAGLUMI X10 will further improve efficiency[26]. - The company has obtained CE certification for some nucleic acid detection reagents, enhancing its product offerings in molecular diagnostics[32]. - The company has developed reagents for various clinical applications, including infectious diseases, cardiovascular markers, and tumor markers, with a focus on auxiliary diagnosis[48]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's review[1]. - The company has established a complete governance structure including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[123]. - The board of directors consists of 7 members, including 3 independent directors, fulfilling legal and regulatory requirements[126]. - The company maintains independence from its controlling shareholder, with no interference in decision-making or operational activities, ensuring the protection of other shareholders' interests[125]. - The company has a robust internal control system and governance structure, ensuring compliance with the Shenzhen Stock Exchange's regulations[124]. Investor Relations - The company engaged in multiple investor communications, including phone calls and on-site visits, with various institutions from January to February 2023[116]. - The frequency of interactions suggests a proactive approach to investor relations, with multiple engagements occurring weekly[116]. - The company is likely focusing on enhancing its market presence and investor confidence through these discussions[116]. - The company is expected to disclose its 2023 annual report on May 31, 2023, providing detailed financial performance and strategic insights[117]. - The company is committed to transparency and regular updates to investors regarding its financial health and strategic initiatives[117]. Environmental Responsibility - The company reported a significant increase in water recovery volume, achieving approximately 19,397 cubic meters in 2023, which represents a growth of about 119% compared to 2022[191]. - The company reduced its air conditioning electricity consumption by 10%, saving approximately 786,000 kWh per year by adjusting the temperature settings[188]. - The company has implemented measures to reduce carbon emissions, aligning with national "dual carbon" policies[188]. - The company has actively promoted the use of biodegradable packaging materials to minimize environmental impact[192]. - The company reported no environmental violations or administrative penalties during the reporting period[186]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 10 RMB per 10 shares to all shareholders, based on the total share capital as of the close of trading on the day before the dividend announcement[2]. - The total cash dividend amount for 2022 is 785,718,785 RMB, which represents 100% of the distributable profit[172]. - The company has a profit distribution policy that aligns with relevant laws and regulations, ensuring transparency and fairness[173]. - The company is dedicated to increasing shareholder returns through continuous cash dividends[122]. - The company has not made any changes to its profit distribution policy during the reporting period[168]. Challenges and Risks - The company is facing risks in new product development due to high costs and lengthy R&D cycles, which could lead to project failures if not managed properly[110]. - The domestic in vitro diagnostic industry is experiencing intense competition, particularly from multinational companies that dominate the high-end market[113]. - The company is closely monitoring regulatory changes in the medical sector to adjust its operational strategies accordingly[109]. - The company is enhancing its management of distributors to mitigate risks associated with mismanagement and legal issues[112]. Human Resources and Talent Management - The total number of employees at the end of the reporting period was 2,627, with a decrease compared to the previous year[163]. - The company has established a competitive salary and bonus system, combining short-term and long-term incentives to attract and retain talent[165]. - The professional composition of employees includes 839 production personnel, 526 sales personnel, and 693 R&D personnel, among others[164]. - The company emphasizes continuous internal talent development to align with strategic goals and operational needs[166]. - The company plans to enhance its human resources system to attract and retain talent, fostering a strong corporate culture and employee engagement[108].

[Table_Page] 年报点评|医疗器械 证券研究报告 [新Table_产Title] 业（300832.SZ） [公Tab司le_I评nves级t] 买入 当前价格 66.43元 业绩符合预期，海外试剂业务增长稳健 合理价值 71.84元 前次评级 买入 [ 核Tabl 心e_Su 观mm 点ary] ： 报告日期 2024-04-12  业绩端符合预期。根据公司 23 年年报，公司实现营业收入 39.3 亿元 [相Tab对le_P市icQ场uote表] 现 （YOY+28.97%）；归母净利润为 16.54 亿元（YOY+24.53%）；毛利 率72.96%（YOY+2.7pp），系海外试剂业务收入占比不断提升导致。 42% 29% 业绩增速快系受23年7月底开始的国家政策净化商业环境，加快市场 16% 增速步伐；集采政策驱动公司提高市场集中度；公司品牌影响力驱动海 4% 外业务增长。根据 wind，公司 23 单 Q4 实现营业收入 10.22 亿元 -9%04/23 06/23 08/23 10/23 12/23 02/24 04/24 （YOY+36.16%），归母净利润4.67亿元（YOY+ ...

证券研究报告 公 2024年04月12日 司 报 告 新产业(300832) │ 行 业： 医药生物/医疗器械 公 投资评级： 买入（维持） 司 当前价格： 66.43元 点 海外本地化有序推进，试剂占比稳步提升 目标价格： 79.72元 评 研 事件： 究 基本数据 公司发布 2023年年报，全年实现收入 39.30亿（yoy+28.97%，下同），实 总股本/流通股本(百万股) 785.72/698.37 现归母净利 16.54 亿（yoy+24.53%），实现扣非归母净利 15.47 亿 流通A股市值(百万元) 46,392.93 （yoy+24.72%）。其中2023年Q4 实现收入10.22亿（yoy+36.16%），实现 每股净资产(元) 9.60 归母净利4.67亿（yoy+15.77%），实现扣非归母净利4.46亿（yoy+14.98%）， 资产负债率(%) 8.25 业绩符合预期。拟每10股派发现金红利10元。 一年内最高/最低(元) 83.50/49.86 ➢ 国内外收入稳定增长，装机结构优化 2023 年公司国内市场实现收入26.08亿(yoy+25.53%)，国内仪器收入同比 股价相对 ...

深圳市新产业生物医学工程股份有限公司 募集资金存放与使用情况鉴证报告 大华国际核字第 2400174 号 深圳大华国际会计师事务所(特殊普通合伙) Shenzhen Dahua International CPAs, LLP 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.gov.gov.cn） f gov.cn 与编码 : 报告 深圳市新产业生物医学工程股份有限公司 募集资金存放与使用情况鉴证报告 （2023 年度） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | | 募集资金存放与使用情况鉴证报告 | | 1-2 | | --- | 深圳市新产业生物医学工程股份有限公司 | | 1-4 | | | 2023 年度募集资金存放与使用情况的专项报 | | | | 告 | | | | (1))( ) ) ) ( ) 即年福田区鹏程一路上中专题中心 14b 募 集 资 金 存 放 与 使 用 情 况 鉴 证 报 告 大华国际核字第 2400174 号 深圳市新产业生物医学工程股份有限公司全体股东: 我们审核了后附的深圳市新 ...

深圳市新产业生物医学工程股份有限公司 审计报告 大华国际审字第 2400173 号 深 圳 大 华 国 际 会 计 师 事 务 所 (特殊普通合伙 ) Shenzhen Dahua International CPAs, LLP 深圳市新产业生物医学工程股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-8 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-93 | 电 话：0755-88605026 地 址：深圳市福田区鹏程一路广电金融中心14F www.dhc ...

深圳市新产业生物医学工程股份有限公司 2023 年度会计师事务所履职情况评估报告 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）聘请深圳大 华国际会计师事务所（特殊普通合伙）（以下简称"深圳大华国际"或"深圳大 华国际会计师事务所"）作为公司 2023 年度财务报告审计机构。根据财政部、国 资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管理办法》，公司 对深圳大华国际 2023 年度审计中的履职情况进行了评估。经评估，公司认为， 近一年深圳大华国际资质等方面合规有效，履职能够保持独立性，勤勉尽责，公 允表达意见，具体情况如下： 一、 2023 年度会计师事务所基本情况 (一)会计师事务所基本情况 机构名称：深圳大华国际会计师事务所（特殊普通合伙） 成立日期：2005 年 1 月 12 日 组织形式：特殊普通合伙 注册地址：深圳市福田区莲花街道福新社区鹏程一路 9 号广电金融中心 14F 首席合伙人：张建栋 截止 2023 年 12 月 31 日，深圳大华国际合伙人人数 21 人，注册会计师人数 69 人，签署过证券服务业务审计报告的注册会计师人数 35 人。 2022 年度，深圳大华国际经审 ...

证券代码：300832 证券简称：新产业 公告编号：2024-022 深圳市新产业生物医学工程股份有限公司 2023 年度内部控制自我评价报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司全体股东： 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合深圳市新产业医学工程股份有限 公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司截至 2023 年 12 月 31 日的内部控制有效性进行了 评价。 一、 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性 ...